_id
695fb6afc2e91020a7bd421f
Ticker
0HIY.LSE
Name
Atara Biotherapeutics, Inc.
Exchange
LSE
Address
1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320
Country
UK
Sector
Industry
Currency
USD
Website
https://www.atarabio.com
Description
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Last Close
15.5
Volume
765
Current Price
15.49
Change
0.4844
Last Updated
2026-01-08T13:52:46.913Z
Ipo Date
-
Market Cap
38986563200
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
3453000
Cost Of Revenue
115000
Gross Profit
3338000
Operating Expenses
6885000
Operating Income
-3547000
Interest Expense
909000
Pretax Income
-4275000
Net Income
-4303000
Eps
-0.3172368033028605
Dividends Per Share
-
Shares Outstanding
45648300
Income Tax Expense
28000
EBITDA
-3330000
Operating Margin
-102.72227048942948
Total Other Income Expense Net
-728000
Cash
5742000
Short Term Investments
7970000
Receivables
1913000
Inventories
-
Total Current Assets
18432000
Property Plant Equipment
10854000
Total Assets
30167000
Payables
318000
Short Term Debt
11623000
Long Term Debt
-
Total Liabilities
66801000
Equity
-36634000
Bs_currency_symbol
-
Depreciation
36000
Change In Working Capital
-7877000
Cash From Operations
-9787000
Capital Expenditures
0
Cash From Investing
-2421000
Cash From Financing
1046999
Net Change In Cash
-11161000
Cf_currency_symbol
-
PE
-
PB
-5.7352830703717865
ROE
11.745919091554294
ROA
-14.263930785295189
FCF
-9787000
Fcf Percent
-2.8343469446857803
Piotroski FScore
0
Health Score
23
Deep Value Investing Score
1
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
6.3
Garp Investing Score
1.5
Growth Investing Score
1.5
Momentum Investing Score
7
Net Net Investing Score
0.5
Quality Investing Score
1.5
Value Investing Score
2
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
3453000
Quarters > 0 > income Statement > cost Of Revenue
115000
Quarters > 0 > income Statement > gross Profit
3338000
Quarters > 0 > income Statement > operating Expenses
6885000
Quarters > 0 > income Statement > operating Income
-3547000
Quarters > 0 > income Statement > interest Expense
909000
Quarters > 0 > income Statement > pretax Income
-4275000
Quarters > 0 > income Statement > net Income
-4303000
Quarters > 0 > income Statement > eps
-0.3172368033028605
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
13564000
Quarters > 0 > income Statement > income Tax Expense
28000
Quarters > 0 > income Statement > EBITDA
-3330000
Quarters > 0 > income Statement > operating Margin
-102.72227048942948
Quarters > 0 > income Statement > total Other Income Expense Net
-728000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
5742000
Quarters > 0 > balance Sheet > short Term Investments
7970000
Quarters > 0 > balance Sheet > receivables
1913000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
18432000
Quarters > 0 > balance Sheet > property Plant Equipment
10854000
Quarters > 0 > balance Sheet > total Assets
30167000
Quarters > 0 > balance Sheet > payables
318000
Quarters > 0 > balance Sheet > short Term Debt
11623000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
66801000
Quarters > 0 > balance Sheet > equity
-36634000
Quarters > 0 > balance Sheet > currency_symbol
-
Quarters > 0 > cash Flow > net Income
-4303000
Quarters > 0 > cash Flow > depreciation
36000
Quarters > 0 > cash Flow > change In Working Capital
-7877000
Quarters > 0 > cash Flow > cash From Operations
-9787000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-2421000
Quarters > 0 > cash Flow > cash From Financing
1046999
Quarters > 0 > cash Flow > net Change In Cash
-11161000
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.3172368033028605
Quarters > 0 > ratios > PB
-5.7352830703717865
Quarters > 0 > ratios > ROE
11.745919091554294
Quarters > 0 > ratios > ROA
-14.263930785295189
Quarters > 0 > ratios > FCF
-9787000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-2.8343469446857803
Quarters > 0 > health Score
23
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
17575000
Quarters > 1 > income Statement > cost Of Revenue
554000
Quarters > 1 > income Statement > gross Profit
17021000
Quarters > 1 > income Statement > operating Expenses
13824000
Quarters > 1 > income Statement > operating Income
3197000
Quarters > 1 > income Statement > interest Expense
972000
Quarters > 1 > income Statement > pretax Income
2390000
Quarters > 1 > income Statement > net Income
2387000
Quarters > 1 > income Statement > eps
0.19390739236393176
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
12310000
Quarters > 1 > income Statement > income Tax Expense
3000
Quarters > 1 > income Statement > EBITDA
3598000
Quarters > 1 > income Statement > operating Margin
18.190611664295876
Quarters > 1 > income Statement > total Other Income Expense Net
-807000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
16903000
Quarters > 1 > balance Sheet > short Term Investments
5420000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
24772000
Quarters > 1 > balance Sheet > property Plant Equipment
11203000
Quarters > 1 > balance Sheet > total Assets
36902000
Quarters > 1 > balance Sheet > payables
1762000
Quarters > 1 > balance Sheet > short Term Debt
2242000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
71943000
Quarters > 1 > balance Sheet > equity
-35041000
Quarters > 1 > balance Sheet > currency_symbol
-
Quarters > 1 > cash Flow > net Income
2387000
Quarters > 1 > cash Flow > depreciation
236000
Quarters > 1 > cash Flow > change In Working Capital
-12771000
Quarters > 1 > cash Flow > cash From Operations
-7318000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-5070000
Quarters > 1 > cash Flow > cash From Financing
15304000
Quarters > 1 > cash Flow > net Change In Cash
2916000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
0.19390739236393176
Quarters > 1 > ratios > PB
-5.441679746582574
Quarters > 1 > ratios > ROE
-6.8120202049028284
Quarters > 1 > ratios > ROA
6.468484093003089
Quarters > 1 > ratios > FCF
-7318000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.4163869132290185
Quarters > 1 > health Score
36
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
98149000
Quarters > 2 > income Statement > cost Of Revenue
20439000
Quarters > 2 > income Statement > gross Profit
77710000
Quarters > 2 > income Statement > operating Expenses
38908000
Quarters > 2 > income Statement > operating Income
38802000
Quarters > 2 > income Statement > interest Expense
1017000
Quarters > 2 > income Statement > pretax Income
38010000
Quarters > 2 > income Statement > net Income
38010000
Quarters > 2 > income Statement > eps
3.5029029582526956
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
10851000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
40822000
Quarters > 2 > income Statement > operating Margin
39.53377008425964
Quarters > 2 > income Statement > total Other Income Expense Net
-792000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
13841000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
8875000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
27182000
Quarters > 2 > balance Sheet > property Plant Equipment
32012000
Quarters > 2 > balance Sheet > total Assets
62038000
Quarters > 2 > balance Sheet > payables
1384000
Quarters > 2 > balance Sheet > short Term Debt
28321000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
117110000
Quarters > 2 > balance Sheet > equity
-55072000
Quarters > 2 > balance Sheet > currency_symbol
-
Quarters > 2 > cash Flow > net Income
38010000
Quarters > 2 > cash Flow > depreciation
1795000
Quarters > 2 > cash Flow > change In Working Capital
-82113000
Quarters > 2 > cash Flow > cash From Operations
-28138000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
17199000
Quarters > 2 > cash Flow > cash From Financing
-250000
Quarters > 2 > cash Flow > net Change In Cash
-11189000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
3.5029029582526956
Quarters > 2 > ratios > PB
-3.0520407829750145
Quarters > 2 > ratios > ROE
-69.0187391051714
Quarters > 2 > ratios > ROA
61.268899706631416
Quarters > 2 > ratios > FCF
-28138000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.28668656838072726
Quarters > 2 > health Score
39
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
32753000
Quarters > 3 > income Statement > cost Of Revenue
6795000
Quarters > 3 > income Statement > gross Profit
25958000
Quarters > 3 > income Statement > operating Expenses
38161000
Quarters > 3 > income Statement > operating Income
-12203000
Quarters > 3 > income Statement > interest Expense
1017000
Quarters > 3 > income Statement > pretax Income
-12712000
Quarters > 3 > income Statement > net Income
-12693000
Quarters > 3 > income Statement > eps
-1.1873713751169317
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
10690000
Quarters > 3 > income Statement > income Tax Expense
-19000
Quarters > 3 > income Statement > EBITDA
-10595000
Quarters > 3 > income Statement > operating Margin
-37.25765578725613
Quarters > 3 > income Statement > total Other Income Expense Net
-509000
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
25030000
Quarters > 3 > balance Sheet > short Term Investments
17466000
Quarters > 3 > balance Sheet > receivables
1482000
Quarters > 3 > balance Sheet > inventories
10655000
Quarters > 3 > balance Sheet > total Current Assets
64894000
Quarters > 3 > balance Sheet > property Plant Equipment
41101000
Quarters > 3 > balance Sheet > total Assets
109098000
Quarters > 3 > balance Sheet > payables
4367000
Quarters > 3 > balance Sheet > short Term Debt
13917000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
206381000
Quarters > 3 > balance Sheet > equity
-97283000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-12693000
Quarters > 3 > cash Flow > depreciation
1100000
Quarters > 3 > cash Flow > change In Working Capital
-22405000
Quarters > 3 > cash Flow > cash From Operations
-24471000
Quarters > 3 > cash Flow > capital Expenditures
90000
Quarters > 3 > cash Flow > cash From Investing
3376000
Quarters > 3 > cash Flow > cash From Financing
-328000
Quarters > 3 > cash Flow > net Change In Cash
-21423000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.1873713751169317
Quarters > 3 > ratios > PB
-1.7021278126702506
Quarters > 3 > ratios > ROE
13.047500591059075
Quarters > 3 > ratios > ROA
-11.634493757905737
Quarters > 3 > ratios > FCF
-24561000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-0.7498855066711446
Quarters > 3 > health Score
24
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
128940000
Annuals > 0 > income Statement > cost Of Revenue
21009000
Annuals > 0 > income Statement > gross Profit
107931000
Annuals > 0 > income Statement > operating Expenses
191369000
Annuals > 0 > income Statement > operating Income
-83438000
Annuals > 0 > income Statement > interest Expense
4615000
Annuals > 0 > income Statement > pretax Income
-85415000
Annuals > 0 > income Statement > net Income
-85403000
Annuals > 0 > income Statement > eps
-11.40531517094017
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
7488000
Annuals > 0 > income Statement > income Tax Expense
-12000
Annuals > 0 > income Statement > EBITDA
-75749000
Annuals > 0 > income Statement > operating Margin
-64.71071816348689
Annuals > 0 > income Statement > total Other Income Expense Net
-1977000
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
25030000
Annuals > 0 > balance Sheet > short Term Investments
17466000
Annuals > 0 > balance Sheet > receivables
1482000
Annuals > 0 > balance Sheet > inventories
10655000
Annuals > 0 > balance Sheet > total Current Assets
64894000
Annuals > 0 > balance Sheet > property Plant Equipment
41101000
Annuals > 0 > balance Sheet > total Assets
109098000
Annuals > 0 > balance Sheet > payables
4367000
Annuals > 0 > balance Sheet > short Term Debt
13917000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
206381000
Annuals > 0 > balance Sheet > equity
-97283000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-85403000
Annuals > 0 > cash Flow > depreciation
5051000
Annuals > 0 > cash Flow > change In Working Capital
-30959000
Annuals > 0 > cash Flow > cash From Operations
-68717000
Annuals > 0 > cash Flow > capital Expenditures
246000
Annuals > 0 > cash Flow > cash From Investing
8624000
Annuals > 0 > cash Flow > cash From Financing
59282000
Annuals > 0 > cash Flow > net Change In Cash
-811000
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-11.40531517094017
Annuals > 0 > ratios > PB
-1.1922855997450736
Annuals > 0 > ratios > ROE
87.7882055446481
Annuals > 0 > ratios > ROA
-78.28099506865387
Annuals > 0 > ratios > FCF
-68963000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-0.5348456646502249
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
8573000
Annuals > 1 > income Statement > cost Of Revenue
8886000
Annuals > 1 > income Statement > gross Profit
-313000
Annuals > 1 > income Statement > operating Expenses
275693000
Annuals > 1 > income Statement > operating Income
-276006000
Annuals > 1 > income Statement > interest Expense
5285000
Annuals > 1 > income Statement > pretax Income
-276111000
Annuals > 1 > income Statement > net Income
-276126000
Annuals > 1 > income Statement > eps
-65.17816677996828
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
4236480
Annuals > 1 > income Statement > income Tax Expense
15000
Annuals > 1 > income Statement > EBITDA
-265997000
Annuals > 1 > income Statement > operating Margin
-3219.4797620436257
Annuals > 1 > income Statement > total Other Income Expense Net
-105000
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
25841000
Annuals > 1 > balance Sheet > short Term Investments
25884000
Annuals > 1 > balance Sheet > receivables
34108000
Annuals > 1 > balance Sheet > inventories
9706000
Annuals > 1 > balance Sheet > total Current Assets
101869000
Annuals > 1 > balance Sheet > property Plant Equipment
58791000
Annuals > 1 > balance Sheet > total Assets
165504000
Annuals > 1 > balance Sheet > payables
3684000
Annuals > 1 > balance Sheet > short Term Debt
12179000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
264735000
Annuals > 1 > balance Sheet > equity
-99231000
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-276126000
Annuals > 1 > cash Flow > depreciation
4829000
Annuals > 1 > cash Flow > change In Working Capital
15341000
Annuals > 1 > cash Flow > cash From Operations
-192977000
Annuals > 1 > cash Flow > capital Expenditures
1223000
Annuals > 1 > cash Flow > cash From Investing
123866000
Annuals > 1 > cash Flow > cash From Financing
2010000
Annuals > 1 > cash Flow > net Change In Cash
-67101000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-65.17816677996828
Annuals > 1 > ratios > PB
-0.6613162741481996
Annuals > 1 > ratios > ROE
278.2658644979895
Annuals > 1 > ratios > ROA
-166.8394721577726
Annuals > 1 > ratios > FCF
-194200000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-22.6525137058206
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
63573000
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
63573000
Annuals > 2 > income Statement > operating Expenses
344086000
Annuals > 2 > income Statement > operating Income
-280513000
Annuals > 2 > income Statement > interest Expense
373000
Annuals > 2 > income Statement > pretax Income
-228290000
Annuals > 2 > income Statement > net Income
-228302000
Annuals > 2 > income Statement > eps
-55.96185900578488
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
4079600
Annuals > 2 > income Statement > income Tax Expense
12000
Annuals > 2 > income Statement > EBITDA
-222264000
Annuals > 2 > income Statement > operating Margin
-441.2454973023139
Annuals > 2 > income Statement > total Other Income Expense Net
52223000
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
92942000
Annuals > 2 > balance Sheet > short Term Investments
149877000
Annuals > 2 > balance Sheet > receivables
40221000
Annuals > 2 > balance Sheet > inventories
1586000
Annuals > 2 > balance Sheet > total Current Assets
295080000
Annuals > 2 > balance Sheet > property Plant Equipment
74322000
Annuals > 2 > balance Sheet > total Assets
376420000
Annuals > 2 > balance Sheet > payables
6871000
Annuals > 2 > balance Sheet > short Term Debt
13640000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
249780000
Annuals > 2 > balance Sheet > equity
126640000
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-228302000
Annuals > 2 > cash Flow > depreciation
5653000
Annuals > 2 > cash Flow > change In Working Capital
-61468000
Annuals > 2 > cash Flow > cash From Operations
-270430000
Annuals > 2 > cash Flow > capital Expenditures
4193000
Annuals > 2 > cash Flow > cash From Investing
202956000
Annuals > 2 > cash Flow > cash From Financing
53084000
Annuals > 2 > cash Flow > net Change In Cash
-14390000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-55.96185900578488
Annuals > 2 > ratios > PB
0.4989971888818699
Annuals > 2 > ratios > ROE
-180.27637397346808
Annuals > 2 > ratios > ROA
-60.650868710482975
Annuals > 2 > ratios > FCF
-274623000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-4.319805577839649
Annuals > 2 > health Score
24
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
20340000
Annuals > 3 > income Statement > cost Of Revenue
282001000
Annuals > 3 > income Statement > gross Profit
-261661000
Annuals > 3 > income Statement > operating Expenses
78801000
Annuals > 3 > income Statement > operating Income
-340462000
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-340095000
Annuals > 3 > income Statement > net Income
-340141000
Annuals > 3 > income Statement > eps
-90.78173374613003
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
3746800
Annuals > 3 > income Statement > income Tax Expense
46000
Annuals > 3 > income Statement > EBITDA
-331117000
Annuals > 3 > income Statement > operating Margin
-1673.8544739429694
Annuals > 3 > income Statement > total Other Income Expense Net
367000
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
106084000
Annuals > 3 > balance Sheet > short Term Investments
264984000
Annuals > 3 > balance Sheet > receivables
986000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
384621000
Annuals > 3 > balance Sheet > property Plant Equipment
79939000
Annuals > 3 > balance Sheet > total Assets
468127000
Annuals > 3 > balance Sheet > payables
17368000
Annuals > 3 > balance Sheet > short Term Debt
2753000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
188513000
Annuals > 3 > balance Sheet > equity
279614000
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-340141000
Annuals > 3 > cash Flow > depreciation
9345000
Annuals > 3 > cash Flow > change In Working Capital
52584000
Annuals > 3 > cash Flow > cash From Operations
-220522000
Annuals > 3 > cash Flow > capital Expenditures
10580000
Annuals > 3 > cash Flow > cash From Investing
22258000
Annuals > 3 > cash Flow > cash From Financing
103944000
Annuals > 3 > cash Flow > net Change In Cash
-94320000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-90.78173374613003
Annuals > 3 > ratios > PB
0.20756447102076434
Annuals > 3 > ratios > ROE
-121.64662713598031
Annuals > 3 > ratios > ROA
-72.65998329513145
Annuals > 3 > ratios > FCF
-231102000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-11.361946902654868
Annuals > 3 > health Score
29
Valuation > metrics > PE
-0.3172368033028605
Valuation > metrics > PB
-5.7352830703717865
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
11.745919091554294
Profitability > metrics > ROA
-23.34526909722222
Profitability > metrics > Net Margin
-1.2461627570228786
Profitability > final Score
23
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-3.902090209020902
Risk > final Score
14
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.543589314127795
Liquidity > metrics > Quick Ratio
1.543589314127795
Liquidity > final Score
89
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
50
Prev Profitabilities > 0
49
Prev Profitabilities > 1
60
Prev Profitabilities > 2
26
Prev Risks > 0
43
Prev Risks > 1
70
Prev Risks > 2
-18
Prev Liquidities > 0
100
Prev Liquidities > 1
56
Prev Liquidities > 2
100
Updated At
2026-01-22T21:22:56.952Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-05
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-0.46
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Stock Price
$0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of Atara Biotherapeutics, Inc.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
-0.46
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.